RAB31 and gastric adenocarcinoma: The 10-year survival rate of patients with high Rab31 was 43%, while the 10-year survival rate of low Rab31 group was 57%, further confirming that high Rab31 is closely correlated with poor survival in STAD patients (Fig. 1G-H).